Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Speedel Could Market Blood Clot Candidate On Its Own

This article was originally published in The Pink Sheet Daily

Executive Summary

After Abbott announces it will not exercise a license-back option, the Swiss firm is considering several options.

You may also be interested in...



Tekturna Launch Anticipated “Very Quickly” Following Approval

Novartis has recruited an additional 1,000 sales reps in preparation for the launch of the antihypertensive, according to partner Speedel.

Tekturna Launch Anticipated “Very Quickly” Following Approval

Novartis has recruited an additional 1,000 sales reps in preparation for the launch of the antihypertensive, according to partner Speedel.

Novartis/Speedel Anti-Hypertensive Rasilez Could Reach Market By Year-End

NDA for the oral renin inhibitor, submitted in the first quarter, seeks monotherapy and combination treatment claims.

Topics

UsernamePublicRestriction

Register

PS064684

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel